MarketCap
Facebook
X
Telegram
Brickell Biotech Income Statement 2023-2008 | BBI
Brief overview of financial results at Brickell Biotech
The conclusions below are based on five years of reported results. Revenue at Brickell Biotech moved from $124 thousand in 2018 to $8 million in 2023. The five-year change reached +6356.5%, while CAGR stood at 130.1%. Revenue growth reflects a pronounced phase of business expansion.
Over the period, EBITDA shifted from −3.5 million dollars to −6.3 million dollars, a change of −83.2%. Operating performance weakened relative to revenue. Comparing the endpoints gives EBITDA margins of −2782.3% and −78.9%. The company improved its ability to convert sales into EBITDA.
Across the five years, the net result shifted from −$3.7 million to −$5.7 million. The loss widened and increased the financial risk.
What the figures show
The results present an uneven picture without one dominant signal. Key strengths include sales growth and higher operating efficiency. Caution is warranted because of a low EBITDA margin and declining net profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Brickell Biotech
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
11.4 M | 5.93 M | 375 K | 29.2 M | 8.86 M | 4.23 M | 138 M | 149 M | 231 M | 634 M | 9.24 B | 19.3 B | 16.1 B | - | - | - |
Shares |
5.39 M | 2.81 M | 1.78 M | 24.5 M | 3.02 M | 587 K | 12.9 M | 10 M | 9.18 M | 8.88 M | 86.8 M | 86 M | 72 M | 60.1 M | - | - |
Historical Prices |
2.11 | 2.11 | 0.21 | 1.19 | 2.93 | 7.21 | 10.7 | 14.9 | 25.2 | 71.4 | 106 | 224 | 224 | - | - | - |
Net Income |
-5.69 M | -21.1 M | -39.5 M | -20.9 M | -23.9 M | -3.67 M | -3.73 M | -8.97 M | -9.24 M | -16.5 M | -31.2 M | -22.9 M | -7.28 M | -30.4 M | -28.6 M | - |
Revenue |
8.01 M | 6.94 M | 404 K | 1.82 M | 7.92 M | 124 K | 3.95 M | 14.5 M | 21 M | 15.2 M | 7.72 M | 17.5 M | 30 M | 8.71 M | 12.7 M | - |
Gross Profit |
- | - | - | 1.82 K | - | 186 K | 7.34 M | 8.24 M | 10 M | 4.39 M | -4.98 M | 17.5 M | 19.8 M | - | - | - |
Operating Income |
-6.36 M | -21.5 M | -40.2 M | -21 M | -24.5 M | -3.6 M | -13.4 M | -9.18 M | -9.4 M | -16.6 M | -31.4 M | -23.4 M | -7.82 M | -31.2 M | -28.6 M | - |
Interest Expense |
5 K | 9 K | 69 K | - | 2.1 M | 1.09 M | - | - | - | - | - | - | - | - | 2 K | - |
EBITDA |
-6.32 M | -21.5 M | -40.2 M | -21 M | -24.4 M | -3.45 M | -12.6 M | -8.06 M | -8.24 M | -15 M | -29.1 M | -21.1 M | -5.32 M | -28.4 M | -26 M | - |
Operating Expenses |
14.4 M | 28.5 M | 40.6 M | 22.8 M | 32.4 M | 19.3 M | 27.2 M | 23.7 M | 9.24 M | 9.5 M | 39.1 M | 41 M | 37.8 M | 39.9 M | 41.3 M | - |
General and Administrative Expenses |
11.2 M | 14.4 M | 12.4 M | 11.6 M | 12.2 M | 6.38 M | 6.34 M | 7.06 M | 8.37 M | 9.55 M | 11.8 M | 10.6 M | 9.6 M | 8.8 M | 7.47 M | - |
All numbers in USD currency
Quarterly Income Statement Brickell Biotech
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
5.91 M | 5.91 M | 3.76 M | 3.02 M | 2.91 M | 2.66 M | 119 M | 119 M | 83.4 M | 68.9 M | 61.2 M | 53.6 M | 28.1 M | 11.8 M | 9.11 M | 8.48 M | 2.94 M | 22.8 M | 22 M | 589 K | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 11.5 M | 11.1 M | 11.1 M | 11.1 M | 10.5 M | 9.24 M | 92.2 M | 9.15 M | 92 M | 91.9 M | 90.9 M | 90.3 M | 90 M | 87.3 M | 87.1 M | 86.8 M | 87 M | 86.7 M | 86.6 M | 86.1 M | 86.4 M | 86.3 M | 84.5 M | 71.9 M | 72.1 M | 71.8 M | 71.9 M |
Net Income |
2.1 M | -2.28 M | -4.28 M | - | -6.02 M | -1.15 M | -9.41 M | - | -13.3 M | -11.1 M | -9 M | - | -4.33 M | -5.12 M | -4.1 M | -10.9 M | -4.78 M | -2.43 M | -4.58 M | -3.67 M | -1.51 M | -4.87 M | -6.27 M | -3.73 M | -3.09 M | -3.32 M | -2.82 M | -2.77 M | -2.52 M | -1.26 M | -2.42 M | -2.36 M | -300 K | -2.76 M | -3.82 M | -4.63 M | -4.36 M | -4.04 M | -3.46 M | -2.19 M | -9.88 M | -9.88 M | -9.28 M | -7.55 M | -7.73 M | -7.87 M | 244 K | -6.61 M | 16.4 M | -8.41 M | -8.69 M |
Revenue |
7.94 M | 53 K | 9 K | - | 486 K | 4.32 M | 92 K | - | 132 K | 151 K | 17 K | - | 142 K | 607 K | 1.05 M | 669 K | 1.18 M | - | - | 124 K | 47 K | 735 K | 716 K | 3.95 M | 3.24 M | 3.42 M | 3.2 M | 3.16 M | 2.64 M | 4.12 M | 4.6 M | 6.81 M | 5.02 M | 4.18 M | 4.94 M | 4.82 M | 3.44 M | 4.5 M | 2.45 M | 3.14 M | 1.54 M | 1.46 M | 1.57 M | 2.32 M | 2.18 M | 1.56 M | 11.5 M | 1.93 M | 26.6 M | 818 K | 649 K |
Operating Income |
2 M | -2.36 M | -4.34 M | - | -6.08 M | -1.46 M | -9.41 M | - | -13.4 M | -11.6 M | -9 M | - | -4.35 M | -5.13 M | -4.1 M | -10.8 M | -6.06 M | -3 M | -5.26 M | -3.6 M | -4.07 M | -5.13 M | -6.5 M | - | -3.18 M | -3.41 M | -2.91 M | - | -2.57 M | -1.32 M | -2.51 M | - | -333 K | -2.79 M | -3.86 M | - | -4.4 M | -4.06 M | -3.48 M | - | -9.98 M | -9.84 M | -9.31 M | - | -7.78 M | -7.94 M | -140 K | - | 16.4 M | -8.45 M | -8.72 M |
Interest Expense |
- | 2 K | 3 K | - | - | 2 K | 4 K | - | 1 K | 30 K | 34 K | - | - | - | - | - | 1.1 M | 660 K | 224 K | - | 267 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
2.03 M | -2.34 M | -4.33 M | - | -6.06 M | -1.44 M | -9.4 M | - | -13.3 M | -11.6 M | -9 M | - | -4.34 M | -5.12 M | -4.1 M | -10.8 M | -6.03 M | -2.98 M | -5.24 M | -3.6 M | -3.93 M | -5.08 M | -6.46 M | - | -2.46 M | -2.88 M | -2.65 M | - | -1.74 M | -765 K | -2.23 M | - | 551 K | -2.2 M | -3.56 M | - | -3.07 M | -3.12 M | -3.02 M | - | -8.25 M | -8.82 M | -8.8 M | - | -6.3 M | -6.96 M | 353 K | - | 18.1 M | -7.29 M | -8.14 M |
Operating Expenses |
5.95 M | 2.42 M | 4.35 M | - | 6.56 M | 5.77 M | 9.5 M | - | 13.5 M | 11.7 M | 9.02 M | - | 4.49 M | 5.73 M | 5.14 M | - | 7.24 M | 5.55 M | 8.08 M | - | 5.34 M | - | - | - | - | - | - | - | - | - | 7.11 M | 9.24 M | 5.35 M | 6.97 M | 8.8 M | 9.5 M | 7.84 M | 8.57 M | 5.93 M | 5.37 M | 11.5 M | 11.3 M | 10.9 M | 9.9 M | 9.96 M | 9.5 M | 11.6 M | 8.98 M | 10.2 M | 9.27 M | 9.37 M |
General and Administrative Expenses |
5.32 M | 1.81 M | 2.41 M | - | 3 M | 3.91 M | 3.49 M | - | 3.27 M | 2.89 M | 2.97 M | - | 3.21 M | 3.02 M | 2.48 M | - | 3.9 M | 2.24 M | 1.38 M | - | 1.61 M | 2.26 M | 2.12 M | - | 1.64 M | 1.59 M | 1.51 M | - | 1.62 M | 1.92 M | 1.79 M | - | 1.92 M | 2.13 M | 2.22 M | - | 2.37 M | 2.54 M | 2.27 M | - | 3.12 M | 3.48 M | 3.52 M | - | 2.42 M | 2.78 M | 2.7 M | - | 2.38 M | 2.45 M | 2.33 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Brickell Biotech (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Germany
China
Israel
France
Britain
Belgium
